ACET

SEC source: 0000950170-24-070577 · ownership.xml · derivative · entry 2

Peng Katie · CIK 0001983850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070577 · ownership.xml · nonDerivative · entry 1

Peng Katie · CIK 0001983850 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,900

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-070575 · ownership.xml · derivative · entry 2

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070575 · ownership.xml · nonDerivative · entry 1

Sinclair Andrew · CIK 0001762451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-070632 · ownership.xml · derivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 336,911

Underlying: Common Stock · 336,911 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-070630 · ownership.xml · derivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,077

Underlying: Common Stock · 375,077 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-070628 · ownership.xml · derivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,829

Underlying: Common Stock · 374,829 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-070619 · ownership.xml · derivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,595

Underlying: Common Stock · 271,595 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-070618 · ownership.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,770,427

Underlying: Common Stock · 1,770,427 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-070616 · ownership.xml · derivative · entry 7

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F8 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070616 · ownership.xml · nonDerivative · entry 1

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-070613 · ownership.xml · derivative · entry 2

Chodakewitz Jeffrey · CIK 0001610876 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070613 · ownership.xml · nonDerivative · entry 1

Chodakewitz Jeffrey · CIK 0001610876 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-070610 · ownership.xml · derivative · entry 5

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F5 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070610 · ownership.xml · nonDerivative · entry 1

Jakobovits Aya · CIK 0001823901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-070608 · ownership.xml · derivative · entry 2

DUBIN STEVE · CIK 0001265123 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070608 · ownership.xml · nonDerivative · entry 1

DUBIN STEVE · CIK 0001265123 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-070605 · ownership.xml · derivative · entry 3

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,400

Underlying: Common Stock · 26,400 shares

Expires 2034-06-04

F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-24-070605 · ownership.xml · nonDerivative · entry 2

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,900

SEC source: 0000950170-24-070605 · ownership.xml · nonDerivative · entry 1

Kauffman Michael · CIK 0001364719 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,800

F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-008053 · ownership.xml · nonDerivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,255,985

F1 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F3 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon ("Gordon") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F5 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.

SEC source: 0000950170-24-008053 · ownership.xml · nonDerivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 990,254

F1 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F3 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon ("Gordon") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

SEC source: 0000950170-24-008053 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · Director · 10% owner

OrbiMed Capital GP V LLC · CIK 0001615374 · Director · 10% owner

OrbiMed Capital GP VI LLC · CIK 0001682115 · Director · 10% owner

OrbiMed Genesis GP LLC · CIK 0001808744 · Director · 10% owner

OrbiMed Advisors Israel II Ltd · CIK 0001682093 · Director · 10% owner

OrbiMed Israel GP II, L.P. · CIK 0001682090 · Director · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · Director · 10% owner

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,526,359

F1 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.

F3 · ownership.nature: This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon ("Gordon") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000950170-24-008052 · ownership.xml · nonDerivative · entry 3

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,255,985

F1 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F3 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F5 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis.

SEC source: 0000950170-24-008052 · ownership.xml · nonDerivative · entry 2

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 990,254

F1 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F3 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

F4 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI.

SEC source: 0000950170-24-008052 · ownership.xml · nonDerivative · entry 1

GORDON CARL L · CIK 0001282930 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 7,526,359

F1 · shares: These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.

F3 · ownership.nature: Each of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II and OrbiMed Israel II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II or OrbiMed Israel II is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000950170-24-008051 · ownership.xml · derivative · entry 3

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,134

Underlying: Common Stock · 288,134 shares

Expires 2034-01-23

F3 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-008051 · ownership.xml · nonDerivative · entry 2

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,801

F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-008051 · ownership.xml · nonDerivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,501

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0000950170-24-008050 · ownership.xml · derivative · entry 3

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241,173

Underlying: Common Stock · 241,173 shares

Expires 2034-01-23

F3 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-008050 · ownership.xml · nonDerivative · entry 2

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,511

F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-008050 · ownership.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,811

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0000950170-24-008049 · ownership.xml · derivative · entry 3

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,633

Underlying: Common Stock · 211,633 shares

Expires 2034-01-23

F3 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-008049 · ownership.xml · nonDerivative · entry 2

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,329

F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-008049 · ownership.xml · nonDerivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,629

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0000950170-24-008048 · ownership.xml · derivative · entry 3

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,022

Underlying: Common Stock · 288,022 shares

Expires 2034-01-23

F3 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-008048 · ownership.xml · nonDerivative · entry 2

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,800

F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-008048 · ownership.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,500

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0000950170-24-008046 · ownership.xml · derivative · entry 5

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,116,903

Underlying: Common Stock · 1,116,903 shares

Expires 2034-01-23

F5 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

SEC source: 0000950170-24-008046 · ownership.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,771

F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance.

SEC source: 0000950170-24-008046 · ownership.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,471

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-052845 · doc4.xml · nonDerivative · entry 1

Aftab Blake · CIK 0001886986 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,376

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 5

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,761

F5 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 4

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 43,469

F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $1.32 to $1.35, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

F2 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.

SEC source: 0001209191-23-051473 · doc4.xml · nonDerivative · entry 1

Galimi Francesco · CIK 0001823996 · SVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,458

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-051470 · doc4.xml · nonDerivative · entry 1

Healey Don · CIK 0001643067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,499

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-051468 · doc4.xml · nonDerivative · entry 1

Harvey Brian Nicholas · CIK 0001519432 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,820

F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

SEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 3

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,969

F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $1.33 to $1.38, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request.

SEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 2

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,469

F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act.

SEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 1

Schor Chen · CIK 0001340875 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 37,969

F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act.

F2 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee.